GlassScriptPhysician profile
Hailey M Garrison
NPI 1629590732
$7,206.03
in general payments reported to CMS, 2019-2025
25 companies · $2,099 in 2025
The $2,099 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,275 · 2022: $1,493 · 2023: $786 · 2024: $1,554 · 2025: $2,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398 · Education: $34.95 · Travel and Lodging: $5.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.17 |
| Education | $34.95 |
| Travel and Lodging | $5.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,319.89 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,137.59 | 2021-2025 | |
| Ardelyx, INC. | $908.73 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $776.14 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $557.94 | 2021-2025 | |
| Genzyme Corporation | $360.79 | 2023-2025 | |
| Redhill Biopharma INC. | $339.37 | 2021-2025 | Talicia |
| Phathom Pharmaceuticals, INC. | $291.43 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $261.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $209.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.14 | 2021-2025 | Entyvio |
| Lilly USA, LLC | $193.57 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $161.77 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $129.21 | 2021-2024 | Ocaliva |
| Organon LLC | $111.50 | 2023-2025 | Hadlima |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $40.96 | 2025 | Vowst, Zenpep |
| Celltrion USA INC. | $35.67 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $31.20 | 2022 | |
| Braintree Laboratories, INC. | $30.73 | 2022-2024 | Suflave |
| Intra-Sana Laboratories | $30.20 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ipsen Biopharmaceuticals, INC | $21.06 | 2025 | Iqirvo |
| Vivus LLC | $18.59 | 2025 | Qsymia |
| Novo Nordisk INC | $18.30 | 2025 | Wegovy |
| Exact Sciences Corporation | $15.86 | 2024 | Cologuard Collection Kit |
| Endogastric Solutions, INC | $10.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.